Figure 1 Patient scans showing liver parenchymal lesions (arrows) before ( A ) and after ( B ) treatment course. Thorax CT scans before treatment ( C and F ) and after 3 months ( D and G ) and 7 months ( E and H ) of treatment. PET scans before treatment ( I ) and after 3 months ( J ), 7 mon... More about this image found in Patient scans showing liver parenchymal lesions (arrows) before ( A ) and a...

Figure 2 Patient’s MRD follow-up. MRD: minimal residual disease; MTM mean tumor molecules. More about this image found in Patient’s MRD follow-up. MRD: minimal residual disease; MTM mean tumor mol...

Figure 3 Patient’s treatment timeline. CGP: comprehensive genomic profiling; IO: immuno-oncology therapy; ir-AE: immune-related adverse event; MTB, molecular tumor board; MTM: mean tumor molecules; PARPi: poly (adenosine diphosphate–ribose) polymerase inhibitor; RCC: renal cell carcinoma. More about this image found in Patient’s treatment timeline. CGP: comprehensive genomic profiling; IO: im...

Figure 1 Selinexor: mechanism of action. Exportin 1 (XPO1) oversees the exportation of several nuclear tumor suppressor proteins (p53, pRB1, p21, BRCA1) and oncoprotein mRNA (c-Myc, Bcl-6, Bcla-2, cyclin D1). Selinexor selectively inhibits XPO1, avoiding the exportation of these products and leadi... More about this image found in Selinexor: mechanism of action. Exportin 1 (XPO1) oversees the exportation ...

Figure 1 Prostate-specific antigen (PSA) responses in patients receiving durvalumab and olaparib with a short course of androgen deprivation therapy (ADT). Durable responses (defined by undetectable PSA) off all therapy and with recovered testosterone were seen in two patients. More about this image found in Prostate-specific antigen (PSA) responses in patients receiving durvalumab ...

Figure 2 Peripheral immune correlatives. (A) Baseline myeloid-derived suppressor cells (MDSC) frequency. (B) Longitudinal plasma cytokine measurements. (C) Peripheral T-cell flow phenotyping across treatment visits. C1D1 reflects baseline before treatment with olaparib and durvalumab. Androgen dep... More about this image found in Peripheral immune correlatives. (A) Baseline myeloid-derived suppressor cel...

Figure 1 (A) First-line and (B) second-line treatment regimens overall and by histomolecular group. chemo: chemotherapy; driver: actionable tumor genomic alteration; ICI: immune checkpoint inhibitor; NSQ: nonsquamous; SQ: squamous. More about this image found in (A) First-line and (B) second-line treatment regimens overall and by histom...

Figure 1 Cohort selection. More about this image found in Cohort selection.

Figure 2 Time to first MACE before and after ICI. ICI: immune checkpoint inhibitor; MACE: major adverse cardiovascular event. More about this image found in Time to first MACE before and after ICI. ICI: immune checkpoint inhibitor;...

Figure 1 Proposed pathophysiology of ADC-induced drug-related pneumonitis. ADC: antibody-drug conjugates. More about this image found in Proposed pathophysiology of ADC-induced drug-related pneumonitis. ADC: anti...